Literature DB >> 1384406

Mechanism of tetracycline-hydrochloride-induced pleurodesis. Tetracycline-hydrochloride-stimulated mesothelial cells produce a growth-factor-like activity for fibroblasts.

V B Antony1, K J Rothfuss, S W Godbey, J A Sparks, J W Hott.   

Abstract

Intrapleural instillation of tetracycline hydrochloride (TCN) is an effective means of achieving pleural fibrosis. However, its mechanism of action remains unknown. To evaluate the hypothesis that TCN stimulates pleural mesothelial cells to release growth-factor-like activity for fibroblasts we performed the following experiments. Rat visceral pleural mesothelial cells were incubated with TCN at doses ranging from 0.01 microgram/ml to 100 mg/ml. The conditioned media (CM) were collected after incubation for 2 to 48 h. CM caused fibroblasts to increase incorporation of thymidine when compared with CM that was unexposed to TCN (p less than 0.05). This growth-factor-like activity continued to be produced by mesothelial cells for 48 h after removal of TCN from the medium. There was a dose-response relationship since increasing doses of TCN to as much as 1 mg/ml caused increasing production of growth-factor-like activity without mesothelial cell injury as measured by trypan blue exclusion. The growth factor activity was a competence-type activity. It coeluted with human PDGF at a molecular weight of 31,000. It was heat-stable (100 degrees C for 10 min) and sensitive to trypsin and papain but not to heat-inactivated trypsin. Addition of cycloheximide or actinomycin D inhibited its production. TCN did not have any direct effect on fibroblasts. Bleomycin CM did not contain growth-factor-like activity for fibroblasts. These data demonstrate that TCN stimulates mesothelial cells to release a growth-factor-like activity for fibroblasts. This phenomenon may play an important role in TCN-induced pleural fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384406     DOI: 10.1164/ajrccm/146.4.1009

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  The mesothelial cell and its role in asbestos-induced pleural injury.

Authors:  M Kuwahara; E Kagan
Journal:  Int J Exp Pathol       Date:  1995-06       Impact factor: 1.925

Review 3.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 4.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 5.  Malignant pleural effusion and algorithm management.

Authors:  Konstantinos Zarogoulidis; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Nikolaos Machairiotis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Eirini Terzi; Bojan Zaric; Haidong Huang; Lutz Freitag; Dionysios Spyratos
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

6.  Role of talc modulation on cytokine activation in cancer patients undergoing pleurodesis.

Authors:  Yehuda Schwarz; Alex Star
Journal:  Pulm Med       Date:  2012-03-07

7.  Intralesional Tetracycline Injection, Pinch Technique, and Canthopexy for the Treatment of Severe Festoons: Preliminary Results.

Authors:  Sergio Lessa; João Pontello; Deilton Duarte; Diogo Lobão
Journal:  Aesthet Surg J Open Forum       Date:  2021-11-20

8.  Effect of Minocycline Pleurodesis in Infants With Refractory Chylothorax After Palliative Surgery for Complex Congenital Heart Disease.

Authors:  Kanchi Saito; Hirofumi Saiki; Shigekuni Tsuchiya; Yurie Takizawa; Akira Sato; Takuya Goto; Yukiko Toya; Atsushi Matsumoto; Junichi Koizumi; Kotaro Oyama; Manami Akasaka
Journal:  Cureus       Date:  2022-03-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.